KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Depreciation and Depletion (2016 - 2025)

Historic Depreciation and Depletion for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Q3 2025 value amounting to $9.9 million.

  • Jazz Pharmaceuticals' Depreciation and Depletion rose 2704.82% to $9.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.7 million, marking a year-over-year increase of 3507.83%. This contributed to the annual value of $32.8 million for FY2024, which is 770.09% up from last year.
  • Per Jazz Pharmaceuticals' latest filing, its Depreciation and Depletion stood at $9.9 million for Q3 2025, which was up 2704.82% from $11.9 million recorded in Q2 2025.
  • Jazz Pharmaceuticals' Depreciation and Depletion's 5-year high stood at $11.9 million during Q2 2025, with a 5-year trough of $4.8 million in Q1 2021.
  • In the last 5 years, Jazz Pharmaceuticals' Depreciation and Depletion had a median value of $7.7 million in 2024 and averaged $8.0 million.
  • In the last 5 years, Jazz Pharmaceuticals' Depreciation and Depletion skyrocketed by 6160.08% in 2021 and then tumbled by 299.47% in 2023.
  • Over the past 5 years, Jazz Pharmaceuticals' Depreciation and Depletion (Quarter) stood at $7.3 million in 2021, then grew by 0.23% to $7.3 million in 2022, then rose by 4.14% to $7.6 million in 2023, then rose by 24.4% to $9.5 million in 2024, then grew by 3.83% to $9.9 million in 2025.
  • Its last three reported values are $9.9 million in Q3 2025, $11.9 million for Q2 2025, and $10.4 million during Q1 2025.